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Podocytes play an important role in maintaining glomerular function, and
podocyte injury is a significant component in the pathogenesis of proteinuria.
Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose genetic defi-
ciency and pharmacological inhibition have beneficial effects on renal func-
tion, but its role in podocytes remains unexplored. The objective of this study
was to investigate the contribution of sEH in podocytes to lipopolysaccharide
(LPS)-induced kidney injury. We report increased sEH transcript and protein
expression in murine podocytes upon LPS challenge. To determine the func-
tion of sEH in podocytes in vivo we generated podocyte-specific sEH-deficient
(pod-sEHKO) mice. Following LPS challenge, podocyte sEH-deficient mice
exhibited lower kidney injury, proteinuria, and blood urea nitrogen concen-
trations than controls suggestive of preserved renal function. Also, renal
mRNA and serum concentrations of inflammatory cytokines IL-6, IL-1b,
and TNFa were significantly lower in LPS-treated pod-sEHKO than control
mice. Moreover, podocyte sEH deficiency was associated with decreased
LPS-induced NF-jB and MAPK activation and attenuated endoplasmic
reticulum stress. Furthermore, the protective effects of podocyte sEH defi-
ciency in vivo were recapitulated in E11 murine podocytes treated with a
selective sEH pharmacological inhibitor. Altogether, these findings identify
sEH in podocytes as a contributor to signaling events in acute renal injury
and suggest that sEH inhibition may be of therapeutic value in proteinuria.
Enzymes
Soluble epoxide hydrolase: EC 3.3.2.10.
Abbreviations
ACR, albumin to creatinine ratio; BUN, blood urea nitrogen; CMJ, corticomedullary junction; DHETs, dihydroxyepoxyeicosatrienoic acids;
EETs, epoxyeicosatrienoic acids; GBM, glomerular basement membrane; LPS, lipopolysaccharides; sEHIs, sEH pharmacological inhibitors;
sEH, soluble epoxide hydrolase.
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Introduction
Glomerular disease is characterized by abnormalities
in the glomerular matrix and podocytes [1]. Podocytes
are the major gatekeeper of glomerular filtration and
play a crucial role in maintaining the integrity of the
glomerular basement membrane (GBM). These differ-
entiated epithelial cells possess a unique and complex
organization that renders them vulnerable to stress.
Alterations in podocyte cytoskeleton and migration
over the GBM result in effacement of foot processes
and apical displacement of the slit diaphragm leading
to proteinuria [2]. Proteinuria is an early marker of
podocyte injury and an indicator of renal disease.
Additionally, proteinuria is often detected before the
decline in glomerular filtration rate. Undetected or left
untreated, proteinuria may progress to chronic kidney
disease and even renal failure [3].
Soluble epoxide hydrolase (sEH, encoded by Ephx2)
is a conserved cytosolic enzyme that is highly
expressed in the kidney, liver, and vasculature [4]. The
best understood physiological role of sEH is its meta-
bolism of polyunsaturated fatty acid epoxides into
their corresponding diols; including the conversion of
anti-inflammatory epoxyeicosatrienoic acids (EETs)
into dihydroxyepoxyeicosatrienoic acids (DHETs) [5].
For most biological endpoints, EETs are biologically
more active than DHETs, which are rapidly conju-
gated and excreted [5]. Accordingly, sEH is a major
determinant of EETs bioavailability and a regulator of
numerous biological processes. Studies using whole-
body sEH-deficient mice and selective sEH pharmaco-
logical inhibitors (sEHIs) provide insights into the
functions of sEH. Pharmacological inhibition of sEH
stabilizes EETs and other epoxy fatty acid levels by
preventing their conversion into DHETs or corre-
sponding diols [6]. Inhibition of sEH in vivo is associ-
ated with a variety of beneficial biological outcomes in
distinct rodent disease models including renal disease.
Indeed, inhibition of sEH reduces inflammation and
renal injury in salt-sensitive hypertension and hyper-
tensive type 2 diabetic rats [7–9]. Also, sEH inhibition
attenuates renal interstitial fibrosis in the unilateral
ureteral obstruction mouse model [10]. Whole-body
sEH-deficient mice exhibit reduced renal inflammation
in DOCA-salt hypertension model [11] and reduced
renal injury in the streptozotocin-induced diabetic
mouse model [12]. These studies implicate sEH in renal
function, but the role of sEH in podocytes and its con-
tribution to proteinuria and renal injury, if any,
remain unclear. In the current study, we investigated
the role of sEH in podocytes in lipopolysaccharides
(LPS)-induced renal injury using genetic and
pharmacological approaches and deciphered the under-
lying molecular mechanisms.
Results
LPS challenge increases renal and podocyte sEH
expression
We determined sEH expression in kidneys and podo-
cytes of wild-type mice under basal (saline) and LPS-
treated states. LPS treatment increased renal sEH
expression at both transcript and protein levels con-
comitant with decreased nephrin (a key podocyte pro-
tein) expression as previously reported (Fig. 1A) [13].
Also, sEH transcript and protein expression increased
in podocytes of wild-type mice after LPS challenge
(Fig. 1B). Moreover, sEH expression was determined
in E11 murine kidney podocytes treated with LPS for
6, 12, 18, and 24 h. Immunoblotting revealed a signifi-
cant time-dependent, LPS-induced increase in sEH
expression concomitant with a decrease in nephrin
expression (Fig. 1C). In total, these findings establish
regulation of renal sEH expression upon LPS chal-
lenge and suggest that dysregulation of sEH signaling
may be relevant to podocyte injury.
Podocyte-specific sEH deficiency preserves renal
function under LPS challenge
Lipopolysaccharide-induced upregulation of sEH sug-
gests that it may contribute to signaling events in podo-
cyte injury. To investigate the potential role of sEH in
proteinuria, we generated mice with podocyte-specific
sEH disruption by crossing sEHfl/fl mice to podocin-Cre
transgenic mice as detailed in methods (Fig. 2A–C) [14].
Podocyte sEH-deficient mice (hereafter termed pod-
sEHKO) survived to adulthood and did not display
gross defects in the kidneys. Immunoblots of isolated
podocytes from control and pod-sEHKO mice revealed
a significant reduction of sEH expression in deficient
mice compared with controls (Fig. 2D). sEH expression
in other tissues (adipose, liver, and muscle) was compa-
rable between genotypes suggesting specificity of dele-
tion. Similarly, Ephx2 expression was significantly
reduced in podocytes of sEH-deficient mice compared
with controls (Fig. 2E). Also, coimmunostaining of
sEH in kidney sections of control and pod-sEHKO mice
demonstrated a significant reduction of sEH in podo-
cytes of sEH-deficient mice (Fig. 2F). Thus, pod-
sEHKO mice exhibit efficient and specific sEH genetic
disruption in podocytes and present a suitable experi-
mental model for investigating the potential contribu-
tion of sEH in podocytes to acute renal injury.
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Lipopolysaccharide treatment of control and pod-
sEHKO mice decreased body weight of both genotypes
but to a lesser extent in the latter (Fig. 3A). Moreover,
LPS increased kidney weights in both genotypes but to
a lower level in pod-sEHKO mice (Fig. 3B,C). Urinary
proteins were very low in both control and pod-sEHKO
mice prior to LPS challenge (Fig. 3D). LPS treatment
significantly increased urinary proteins and urinary
albumin/creatinine, but they were lower in pod-sEHKO
mice suggestive of preserved filter integrity and renal
Fig. 1. LPS treatment increases sEH expression in podocytes. (A) Immunoblots of sEH, nephrin, and tubulin in total kidney lysates of
control (saline-treated) and LPS-treated C57BL/6J wild-type male mice. Representative immunoblots are shown, and each lane represents
an animal. Bar graphs represent protein (left panel) and mRNA (right panel) in kidney lysates from control (saline; n = 6) and LPS-treated
(LPS; n = 9) mice and presented as means + SEM. (B) Lysates of podocytes isolated from control and LPS-treated C57BL/6J wild-type male
mice were immunoblotted for sEH, nephrin, and tubulin. Representative immunoblots are shown. Bar graphs represent protein expression
(left panel) and mRNA (right panel) in podocytes and presented as means + SEM. In (A) and (B) *P < 0.05, **P < 0.01 indicate a significant
difference between saline- and LPS-treated mice. (C) sEH, nephrin and tubulin protein expression in differentiated murine E11 podocytes
without (PBS) and with LPS treatment for the indicated times. Bar graph represents sEH and nephrin expression and presented as
means + SEM from three independent experiments. *P < 0.05, **P < 0.01 indicate a significant difference between PBS (24 h) and LPS-
treated groups at the shown time versus PBS (0 h).
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function (Fig. 3D,E). Similarly, and in line with previ-
ous reports [15,16] LPS caused a marked elevation in
blood urea nitrogen (BUN) levels, but that was lower in
pod-sEHKO mice consistent with preserved renal func-
tion (Fig. 3F). Furthermore, and consistent with pub-
lished reports [17–19] LPS led to a significant decrease
in serum albumin levels with concomitant elevated
serum creatinine in control mice (Fig. 3G,H). Podocyte
sEH deficiency mitigated changes in serum albumin and
creatinine levels. Of note, the renal protective effects of
podocyte sEH deficiency were also observed in a second
model (anti-GBM serum treatment of female mice) as
evidenced by urinary albumin/creatinine and BUN
levels (Fig. 3I,J). As early stages of proteinuric diseases
show evidence of glomerular injury and tubular impair-
ment [20], we evaluated histological changes in PAS-
stained kidney sections from control and pod-sEHKO
mice under basal (saline) and LPS-treated states. The
most noticeable morphological changes included acute
tubular injury and Bowman space dilatation which were
diffusely involving renal parenchyma in LPS-treated
control mice, and very focal in control and pod-sEHKO
mice with LPS administration (Fig. 3K, Table 1).
Importantly, LPS-treated pod-sEHKO mice exhibited
significantly less tubular injury and Bowman space
dilatation. Finally, immunostaining of nephrin in kid-
ney sections of control mice revealed decreased nephrin
expression upon LPS challenge (Fig. 3L), consistent
with biochemical findings (in Fig. 1) and published
studies [21]. However, podocyte sEH deficiency miti-
gated the effects of LPS and prevented the decrease in
nephrin expression. Altogether, the aforementioned
findings establish a protective effect of podocyte sEH
deficiency in LPS-induced proteinuria and identify
podocytes as significant contributors to the beneficial
effects of sEH deficiency.
Fig. 2. Efficient and specific deletion of sEH in podocytes. (A) sEH genomic locus and targeting; two loxP sites were designed in an intronic
region of the sEH gene. (B–C) Confirmation of sEH floxed and Cre mice by PCR. Genomic DNA from tails was amplified by PCR; primers
were designed to distinguish the alleles with and without loxP insertions (B), and Cre (C). (D) Immunoblots of sEH expression in podocytes,
epididymal fat, liver, and muscle of control (Ctrl) and pod-sEHKO (KO) mice. Representative immunoblots are shown. (E) Ephx2 expression
in podocytes of control (Ctrl; n = 6) and pod-sEHKO (KO; n = 6) mice. **P < 0.01 indicates a significant difference between Ctrl and KO. (F)
Co-immunostaining of sEH (red) and nephrin (green) in kidney paraffin sections of Ctrl and KO mice. Scale bar: 200 lm.
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Podocyte sEH deficiency mitigates LPS-induced
inflammation
Lipopolysaccharide treatment increases renal and sys-
temic cytokine concentrations [22] and systemic inflam-
matory response [23]. Accordingly, we investigated the
effects of podocyte-specific sEH disruption on LPS-
induced alterations in inflammatory cytokines, namely
interleukin-1b (IL-1b), interleukin-6 (IL-6), and tumor
necrosis factor-a (TNFa). Renal mRNA and serum
concentrations of IL-1b, IL-6, and TNFa were ele-
vated in both control and pod-sEHKO mice after LPS
challenge but were significantly lower in the latter
(Fig. 4A,B). The nuclear factor-kappa B (NF-jB) plays
a significant role in the regulation of IL-1b and TNFa
during LPS-induced renal injury [24,25]. Also, sEH defi-
ciency leads to anti-inflammatory effects through atten-
uation of NF-jB signaling [26]. Accordingly, we
examined renal NF-jB signaling in control and pod-
sEHKO mice under basal and LPS-treated states. LPS-
induced IKKa, IjBa, and NF-jBp65 phosphorylation
and NF-jBp50 expression were significantly less in pod-
sEHKO mice compared with controls (Fig. 4C). This
finding is in line with the reduced proinflammatory
cytokines in pod-sEHKO mice.
Activation of mitogen-activated protein kinases
(MAPKs) including JNK and p38 has been reported
in human renal diseases [27,28]. Also, pharmacological
inhibition of JNK or p38 suppresses proteinuria and
renal injury through attenuating renal inflammation
and fibrosis [27,29,30]. Accordingly, we examined the
activation of JNK and p38 in control and pod-sEHKO
mice under basal and LPS-treated states. LPS treat-
ment increased JNK and p38 phosphorylation in both
control and pod-sEHKO mice but that was signifi-
cantly lower in the latter (Fig. 4D). Collectively, these
findings establish decreased LPS-induced inflammatory
response in pod-sEHKO mice and are consistent with
the protective effects of podocyte sEH deficiency in
LPS-induced renal injury.
Podocyte sEH deficiency attenuates LPS-induced
endoplasmic reticulum stress
Endoplasmic reticulum (ER) stress plays a significant
role in the progression of proteinuria [31] and apopto-
sis in response to severe proteinuria [32]. sEH defi-
ciency and pharmacological inhibition attenuate ER
stress in liver, adipose tissue [26,33], and pancreas
[34,35]. Thus, we examined alterations in ER stress in
control and pod-sEHKO mice under basal and
LPS-treated states. Consistent with published reports
[36–38], LPS induced renal ER stress as evidenced by
Table 1. Histological evaluation of injury in PAS-stained kidney
sections of control and pod-sEHKO mice. Tubules from the cortex
and CMJ regions were examined in PAS-stained kidney sections of
control (Ctrl) and pod-sEHKO (KO) mice without (saline), and with
LPS treatment and were scored as described in methods. The
extent of injury was calculated as follows (number of tubules with
a score higher than 0 9 corresponding score)/total number of
tubules examined (e.g.,: the extent of tubules injury in WT-
LPS = [(217 9 2) + (637 9 1)]/854 = 1.254).
WT-saline
(n = 4)
WT-LPS
(n = 4)
KO-saline
(n = 4)
KO-LPS
(n = 8)
Cortex
Number of tubules
examined
764 854 883 1399
Injury score
7 637 10 80 80
0 217 0 0 0
0 0 0 0 0
0 0 0 1 2
Extent of injury 0.009 1.254 0.011 0.060
CMJ
Number of tubules
examined
781 824 841 1391
Injury score
16 588 59 88 88
0 118 4 6 12
0 3 0 0 0
0 0 3 1 4
Extent of injury 0.020 1.102 0.093 0.066
Fig. 3. Podocyte sEH deficiency attenuates LPS-induced proteinuria. Body (A) and kidney (B) weights, and kidney to body weight ratio (C) of
control (Ctrl) and pod-sEHKO (KO) mice without (saline) and with LPS treatment. Urinary proteins (D), ACR (E), BUN (F), serum albumin (G),
and creatinine (H) from control and pod-sEHKO mice without (saline) and with LPS treatment (n = 9 per group). *P < 0.05, **P < 0.01
indicate a significant difference between mice without and with LPS treatment, and †P < 0.05, ††P < 0.01 indicate a significant difference
between pod-sEHKO and control mice. ACR (I) and BUN (J) from control and pod-sEHKO female mice (n = 5–6/group) after anti-GBM
serum injection. *P < 0.05 indicates a significant difference between pod-sEHKO and control mice. (K) PAS-stained kidney sections of Ctrl
and pod-sEHKO mice without and with LPS treatment. Arrows indicate dilated Bowman space and asterisks indicate dilated tubules. Scale
bar: 200 lm. Images in the right panel are a magnification of the boxed regions. (L) Immunostaining for nephrin (green), and DAPI (blue) in
kidney sections of control Ctrl and pod-sEHKO mice without and with LPS treatment. Scale bar: 50 lm.
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elevated activation of ER transmembrane proteins
PKR-like ER-regulated kinase (PERK) and inositol-
requiring enzyme 1a (IRE1a), and their respective
downstream targets a-subunit of eukaryotic translation
initiation factor 2 (eIF2a) and X-box binding protein
1 (XBP1) (Fig. 5). Importantly, pod-sEHKO mice
exhibited attenuated LPS-induced ER stress as evi-
denced by decreased PERK (Thr980), eIF2a (Ser51),
and IRE1a (Ser724) phosphorylation and XBP1 splic-
ing. Also, pod-sEHKO mice exhibited decreased LPS-
induced caspase3 cleavage compared with controls.
These data establish attenuated LPS-induced renal ER
stress in podocyte sEH-deficient mice.
sEH pharmacological inhibition in vitro
recapitulates the protective effects of podocyte
sEH disruption
The renal response to LPS-induced injury encompasses
many cell types that include glomerular podocytes [39].
To delineate the contribution of sEH in podocytes to
LPS-induced injury we used immortalized E11 murine
podocytes [40]. Differentiated E11 podocytes were
treated with the selective sEH inhibitor TPPU as
detailed in methods, and the effects on LPS-induced
inflammatory response and ER stress were evaluated.
LPS induced activation of NF-jB and MAPK signal-
ing as well as the elevation of ER stress in E11 podo-
cytes (Fig. 6A,B). Importantly, sEH pharmacological
inhibition mitigated the deleterious effects of LPS
treatment in these cells. Indeed, sEH inhibitor-treated
E11 podocytes exhibited lower LPS-induced activation
of NF-jB and MAPK as evidenced by decreased
IKKa, IjBa, NF-jBp65, JNK, and p38 phosphoryla-
tion (Fig. 6A). Similarly, sEH inhibitor-treated podo-
cytes exhibited lower LPS-induced ER stress as
evidenced by decreased PERK, eIF2a, and IRE1a
phosphorylation, and decreased sXBP1 splicing and
caspase3 cleavage (Fig. 6B). These findings are in
keeping with observations in pod-sEHKO mice and
are consistent with autonomous cell effects.
Discussion
Podocytes function under numerous physiological and
pathophysiological stresses to maintain the integrity of
the glomerular filtration barrier. Podocytes adapt to
maintain homeostasis, but excessive stress can cause
podocyte dysfunction and injury that lead to proteinuria
and glomerulosclerosis. The complex cellular and molec-
ular mechanisms underlying podocyte injury and its con-
sequences are not well understood. In the current study,
we investigated the potential contribution of sEH in
podocytes to acute renal injury using genetic and
pharmacological approaches. LPS induced upregula-
tion in sEH transcript and protein levels in podocytes.
Remarkably, podocyte-specific sEH disruption signifi-
cantly attenuated LPS-induced renal dysfunction and
was associated with decreased NF-jB inflammatory
response, MAPK and ER stress signaling. In addition,
the in vivo protective effects of podocyte sEH defi-
ciency were recapitulated in vitro in immortalized
podocytes treated with a selective sEHI. Collectively,
these findings identify sEH as a significant contributor
to signaling events following podocyte injury and sug-
gest that sEH inhibition in podocytes may be of thera-
peutic value in proteinuria.
Several studies implicate the Arachidonic acid cyto-
chrome P450 epoxygenase pathway in glomerular func-
tion and establish a correlation between the decline in
glomerular function and concentrations of EETs.
Streptozotocin-induced diabetes in rats causes a signifi-
cant decrease in glomerular 20-HETE and EETs con-
comitant with increased proteinuria and glomerular
hypertrophy [41]. Also, upregulation of sEH in proxi-
mal tubular cells mediates proteinuria-induced renal
damage [42], while sEH inhibition markedly amelio-
rates proteinuria-induced epithelial–mesenchymal tran-
sition [43]. Moreover, genetic disruption of Ephx2
decreases inflammation and attenuates albuminuria
and renal damage associated with salt-sensitive hyper-
tension [44]. Furthermore, sEH deficiency and pharma-
cological inhibition prevent renal interstitial fibrosis in
unilateral ureteral obstruction models [10,45]. In
Fig. 4. Decreased LPS-induced inflammatory response in podocyte sEH-deficient mice. Renal mRNA (A) and serum (B) levels of IL-1b, IL-6,
and TNFa in saline- and LPS-treated control (n = 6) and pod-sEHKO (n = 6) mice. Serum IL-6 concentration was very low in both control and
pod-sEHKO mice before LPS challenge. (C) Kidney lysates from control and pod-sEHKO mice without (saline) and with LPS treatment were
immunoblotted for pIKKa, pIjBa, pNF-jBp65, their respective unphosphorylated proteins, and Tubulin as a loading control. Representative
immunoblots are shown. Bar graphs represent pIKKa/IKKa, pIΚBa/IΚBa, pNF-jBp65/NF-jBp65, and NF-jBp50/Tubulin as means + SEM. (D)
Kidney lysates from control and pod-sEHKO were immunoblotted for pJNK and pp38 and their respective unphosphorylated proteins.
Representative immunoblots are shown. Bar graphs represent pJNK/JNK and pp38/p38 as means + SEM. *P < 0.05, **P < 0.01 indicate a
significant difference between mice without (saline) and with LPS treatment, and †P < 0.05, ††P < 0.01 indicate a significant difference
between pod-sEHKO and control mice.
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keeping with these reports, the current findings estab-
lish a protective role for podocyte-specific sEH disrup-
tion in acute renal injury. Importantly, the protective
effects of sEH deficiency were observed in two different
mouse models of renal injury including males and
females, demonstrating that they were not specific to
particular challenge or gender. Furthermore, the effects
of podocyte sEH deficiency were recapitulated in podo-
cytes treated with a selective sEH inhibitor consistent
with autonomous effects, but we cannot rule out the
potential contribution of other cell types to the LPS
response. It is worth nothing that the current studies
harbor some limitations. The reagent used in Bradford
assay does not react with urinary proteins that are
smaller than 13 kDa [46]. However, since most proteins
that appear in the urine of patients with glomerular
proteinuria are of intermediate size [39,47–52], the used
methodology is likely suitable. Indeed, the current find-
ings on the effect of LPS on albumin and albumin to
creatinine ratio (ACR) in control mice are consistent
with published reports [21,53,54]. Also, we cannot rule
out that the urinary proteins could have nonfiltration
related causes. Moreover, changes in serum albumin
upon LPS challenge are unlikely to be due to filtration
alone as previous studies demonstrate inhibition of
albumin tubular transcytosis [55], an essential mecha-
nism to preserve serum albumin levels, in response to
acute kidney injury [56,57]. Nevertheless, the current
findings and previous reports suggest that inhibiting
sEH to increase EETs and other epoxy fatty acids
may be of value in combating glomerular injury.
Previous studies implicate podocytes in LPS-induced
proteinuria [39]. Herein, we demonstrate that podo-
cyte-specific sEH genetic disruption in vivo and phar-
macological inhibition in podocytes were associated
with decreased LPS-induced inflammation, MAPK
activation, and ER stress. Inflammation in the glomer-
uli leads to proteinuria [58], and activation of NF-jB
during proteinuric diseases and renal injury has been
documented in glomeruli [59–61]. Therefore, it is rea-
sonable to stipulate that the protective effects of podo-
cyte-specific sEH disruption against acute renal injury
and proteinuria may be mediated, at least partly, by
decreased activation of NF-jB signaling. The underly-
ing mechanism through which sEH deficiency attenu-
ates NF-jB signaling remains to be delineated but can
be related to an overall reduction in inflammation.
The current findings are in line with reports of reduced
renal inflammation in streptozotocin-treated sEH
whole-body knockout mice and sEHI-treated diabetic
mice [12]. Also, podocyte-specific sEH disruption and
pharmacological inhibition impacted other pathways
that contribute to proteinuric kidney disease, namely
ER stress. ER stress is evoked in several kidney dis-
eases (such as membranous nephropathy, proteinuric
renal diseases, and renal fibrosis) and attenuation of
ER stress decreases proteinuria and interstitial fibrosis
and restores renal integrity [62–67]. Similarly, adminis-
tration of the chaperone 4-phenylbutyrate to mitigate
ER stress is associated with improvement in tubular
lesions [62]. Thus, attenuated ER stress in vivo upon
podocyte sEH deficiency and inhibition is in line with
the renal protective effects of podocyte sEH deficiency.
These findings are consistent with our previous studies
demonstrating that sEH deficiency and inhibition
attenuate HFD-induced ER stress in liver and adipose
tissue [33], and in the pancreas during acute pancreati-
tis [34,35]. The mechanism underlying attenuation of
ER stress by sEH deficiency is unclear but may
encompass an increase in EETs and other epoxy fatty
acids and/or decrease in diols, although this still
needs to be demonstrated. As such, upregulation of
sEH in podocytes after LPS challenge may decrease
the concentration of EETs and increase the diols
thereby contributing to elevated ER stress during
podocyte injury. Additional investigation is needed to
decipher the contribution of sEH to ER stress-
mediated podocyte injury and consequences on pro-
teinuric kidney diseases. Nevertheless, the current
study establishes protective effects of podocyte-specific
sEH deficiency against LPS-induced renal injury and
suggests that sEH inhibition in podocytes may have
potential therapeutic implications for combating
podocyte injury.
Materials and methods
Reagents
RPMI medium, penicillin/streptomycin, and trypsin were
purchased from Invitrogen (Carlsbad, CA, USA). FBS was
purchased from Gemini Bio-Products (Sacramento, CA,
Fig. 5. Decreased LPS-induced ER stress in podocyte sEH-deficient mice. Immunoblots of key proteins in ER stress signaling in kidney
lysates from saline- and LPS-treated control and pod-sEHKO mice (n = 6/group). Representative immunoblots are shown. Bar graphs of
pPERK/PERK, peIF2a/eIF2a, pIRE1a/IRE1a, sXBP1/Tubulin, and cleaved caspase3/Tubulin are presented as means + SEM. *P < 0.05,
**P < 0.01 indicate a significant difference between mice without (saline) and with LPS treatment, and ††P < 0.01 indicates a significant
difference between pod-sEHKO and control mice.
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USA). Antibodies used in this study (sources, species, and
conditions of use) are listed in Table 2. Nephrotoxic antis-
era (sheep anti-rat GBM) were purchased from Probetex
(San Antonio, TX, USA). Unless otherwise indicated,
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Fig. 6. Pharmacological inhibition of sEH attenuates LPS-induced inflammatory and ER stress signaling in immortalized podocytes. Immunoblots
of key proteins in inflammation, MAPK, and ER stress signaling in differentiated E11 podocytes without (LPS) and with (+LPS) treatment for
24 h and without () and with (+) sEH pharmacological inhibition (sEHI). Representative immunoblots are shown. Bar graphs of pIKKa/IKKa,
pIΚBa/IΚBa, pNF-jBp65/NF-jB, NF-jBp50/Tubulin, pJNK/JNK, pp38/p38, pPERK/PERK, peIF2a/eIF2a, pIRE1a/IRE1a, sXBP1/Tubulin, and
cleaved Caspase3/Tubulin are presented as means + SEM from three independent experiments. **P < 0.01 indicates a significant difference in
cells without and with LPS treatment. †P < 0.05, ††P < 0.01 indicate a significant difference between nontreated and sEHI-treated cells.
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Mouse studies
sEH floxed (Ephx2fl/fl) mice were generated and kindly pro-
vided by D. Zeldin (NIEHS) and were backcrossed on the
C57Bl/6J background. Transgenic mice expressing Cre
recombinase under control of the podocin promoter on the
C57Bl/6J background were purchased from Jackson Labo-
ratories (Sacramento, CA, USA) [14]. sEH floxed mice
were bred to podocin-Cre mice to generate podocyte-speci-
fic sEH-deficient mice. Genotyping for the Ephx2 floxed
allele and Cre was performed by polymerase chain reaction
using DNA from tails. Mice were maintained on a 12-h
light-dark cycle with free access to water and standard lab-
oratory chow (Purina Lab, St. Louis, MO, USA chow,
#5001). For LPS-induced renal injury, 10–12 week old
pod-sEHKO (Ephx2fl/fl Pod-cre+) and control (Ephx2fl/fl)
male mice were injected once intraperitoneally with LPS
(Sigma-Aldrich; 16 mgkg1 body weight in 0.9% sterile
saline solution). For anti-GBM serum-induced acute kid-
ney injury 8–10-week-old female mice received a single
retro-orbital injection of sheep anti-rat GBM serum
(5 mLkg1 body weight diluted in 0.02 M phosphate buf-
fered saline PBS, pH: 7.3) [58]. Mice were sacrificed 24 h
after LPS, or 24 and 48 h after anti-GBM serum injections
then kidneys were harvested and processed for biochemical
and histological analyses. Urine samples were collected 2 h
before sacrifice in 50-mL conical tubes. Tubes were cen-
trifuged for 1 min at 1000 g then urine (80–200 lL) was
stored at 80 °C until further analyses. Blood samples
(600–800 lL) were collected using the cardiac puncture
method at sacrifice. Proteins were measured in 2 lL urine
samples using the Bio-Rad Protein Assay reagent (BioRad,
Hercules, CA, USA). Also, BUN levels were measured
using the Urea Nitrogen Colorimetric Detection Kit from
Arbor Assays (Ann Arbor, MI, USA). Serum and urine
albumin and creatinine levels were measured using the
BCG Albumin and Creatinine Assay Kits (Sigma-Aldrich),
respectively, according to manufacturer’s instructions. Cir-
culating cytokines were measured using a multiplex electro-
chemiluminescent assay from Meso Scale Discovery
(Rockville, MD, USA). All mouse studies were conducted
according to federal regulations and were approved by the
Institutional Animal Care and Use Committee at the
University of California-Davis.
Histological assessment of renal injury
Kidney sections were fixed in 4% paraformaldehyde,
embedded in paraffin, and deparaffinized in xylene, and
then 5-lm sections were stained with periodic acid Schiff
(PAS) using a commercially available kit (Sigma-Aldrich)
according to manufacturer’ recommendations. Renal injury
was assessed as previously described [68,69] by morphomet-
ric analysis of the tubular damage using the following crite-
ria: no injury (score 0), tubular dilatation and brush border
loss (score 1), tubular epithelial cells vacuolization (score
2), apical blebbing (score 3), and epithelial cells sloughing
(score 4). In each case, 10 high power fields (940) of renal
cortex and corticomedullary junction (CMJ) were scored
separately for acute tubular injury. The extent of the dam-
age was calculated as follows (number of tubules with a
score higher than 0 9 corresponding score)/total number
of tubules examined.
Immunofluorescence
Kidneys from control and pod-sEHKO mice were fixed in
10% formalin and embedded in paraffin. Sections were
coimmunostained for nephrin, sEH, and DAPI. Detection
was performed with appropriate fluorophore-conjugated
secondary antibodies (1 : 500; Invitrogen) and visualized
using Leica DMI8 inverted microscope (Leica Microsys-
tems Inc., Buffalo Grove, IL, USA).
Podocyte isolation and cell culture
Glomeruli were isolated from control and pod-sEHKO
mice using established protocols [70,71] with some
Table 2. List of primary and secondary antibodies and conditions
of use.
Antibodies Source Host Dilution
b-Tubulin Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
Mouse 1 : 20 000
Cleaved
Caspase 3
Cell Signaling Technology
(Danvers, MA, USA)
Rabbit 1 : 5000
eIF2a Santa Cruz Biotechnology Mouse 1 : 500
IKKa Cell Signaling Technology Rabbit 1 : 2500
IRE1 Santa Cruz Biotechnology Rabbit 1 : 1000
IjBa Cell Signaling Technology Rabbit 1 : 2500
JNK1/2 Santa Cruz Biotechnology Rabbit 1 : 5000
Nephrin
(used for IF)
Santa Cruz Biotechnology Goat 1 : 100
Nephrin
(used for WB)
Santa Cruz Biotechnology Rabbit 1 : 1000
NF-jB p65 Cell Signaling Technology Rabbit 1 : 5000
NF-jB p50 Cell Signaling Technology Rabbit 1 : 2500
p38 Santa Cruz Biotechnology Rabbit 1 : 5000
peIF2aS51 Santa Cruz Biotechnology Rabbit 1 : 1000
PERK Santa Cruz Biotechnology Rabbit 1 : 1000
pIKKaS178/180 Cell Signaling Technology Rabbit 1 : 2500
pIRE1S724 Abcam (Cambridge,
MA, USA)
Rabbit 1 : 10 000
pIjBaS32 Cell Signaling Technology Rabbit 1 : 2500
pJNK1/2T183/Y185 Cell Signaling Technology Rabbit 1 : 10 000
pNF-jB p65S536 Cell Signaling Technology Rabbit 1 : 2500
pp38T180/Y182 Cell Signaling Technology Rabbit 1 : 10 000
pPERKT980 Santa Cruz Biotechnology Rabbit 1 : 1000
sEH Dr B. Hammock Laboratory
(Davis, CA, USA)
Rabbit 1 : 10 000
sXBP1 Santa Cruz Biotechnology Goat 1 : 1000
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modifications. Briefly, podocytes were isolated using succes-
sive sieving approach. Kidneys were decapsulated and
minced in Krebs–Henseleit saline solution (KHS; 119 mM
NaCl, 4.7 mM KCl, 1.9 mM CaCl2, 1.2 mM KH2PO4,
1.2 mM MgSO47H2O, and 25 mM NaHCO3, pH: 7.4).
Samples were pelleted at 500 g for 10 min and then washed
twice with KHS buffer. Before the second wash, samples
were passed through a 250 lm sieve and pelleted at 500 g
for 10 min then digested for 30 min at 37 °C in Hanks buf-
fer containing collagenase D (0.1%), trypsin (0.25%), and
DNase I (0.01%). Solutions were filtered through a 100-lm
sieve placed above a 53-lm sieve. Podocytes were cen-
trifuged for 5 min at 1500 g, 4 °C and lysed in radio-
immunoprecipitation assay (RIPA) buffer. Immortalized
E11 murine podocytes (Cell Lines Service, Eppelheim, Ger-
many) were cultured in RPMI containing 11 mM glucose,
10% FBS, 50 UmL1 penicillin, and 50 lgmL1 at 33 °C.
To induce differentiation, cells were transferred to 37 °C
for 14 days [40]. When indicated, podocytes were treated
with freshly prepared LPS (10 lM) for 24 h, or sEH inhibi-
tor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)
urea (TPPU; 10 lM) [72,73] 2 h before LPS treatment.
Biochemical analyses
Tissues and cells were lysed in RIPA buffer as described
[74]. Lysates were clarified by centrifugation at 13 000 g for
10 min, and protein concentrations determined using bicin-
choninic acid assay kit (Pierce Chemical, Dallas, TX, USA).
Proteins (15–30 lg) were resolved by SDS/PAGE and trans-
ferred to PVDF membranes. Immunoblotting of lysates was
performed with primary antibodies, and after incubation
with secondary antibodies, proteins were visualized using
LuminataTM Western Chemiluminescent HRP Substrate
(Millipore Corp., Billerica, MA, USA). Pixel intensities of
immunoreactive bands were quantified using FLUORCHEM Q
IMAGING software (Alpha Innotech Corp., San Jose, CA,
USA). Data for phosphorylated proteins are presented as
phosphorylation normalized to protein expression.
Kidneys from control and pod-sEHKO mice were cut
and immediately placed in extraction reagent (TRIzol;
Invitrogen). RNA was extracted according to the manufac-
turer’s instructions and resuspended in 50 lL of RNase-
free water. The concentration of RNAs was determined
using the NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific Inc., Piscataway, NJ, USA).
Specific DNA products were generated with an RT-PCR
system (high-capacity cDNA Synthesis Kit; Applied Biosys-
tems, Foster City, CA, USA). Primer used are described in
Table 3 and expression of Ephx2, Il-1b, Il-6, and Tnfa was
assessed by quantitative real-time PCR using SsoAdvan-
cedTM Universal SYBR Green Supermix (BioRad) and the
Bio-Rad CFX96TM system. Relative abundance of target
gene mRNA was measured using the ΔΔCT method with
appropriate primers and normalized to Tata box-binding
protein (Tbp) as previously described [34].
Statistical analyses
Data are expressed as means + standard error of the mean
(SEM). All statistical analyses were performed with JMP pro-
gram (SAS Institute Inc., Cary, NC, USA) using an unpaired
heteroscedastic two-tail Student’s t test. Differences were
considered significant at P ≤ 0.05 and highly significant at
P ≤ 0.01. Single symbol (such as *) corresponds to P ≤ 0.05,
while double (such as **) corresponds to P ≤ 0.01.
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